Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Mar;77(3):408-9.
doi: 10.4088/JCP.15l10138.

Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial

Carolyn I Rodriguez  1   2 , Michael Wheaton, Jordana Zwerling, Shari A Steinman, Danae Sonnenfeld, Hanga Galfalvy, Helen Blair Simpson
Affiliations
Clinical Trial

Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial

Carolyn I Rodriguez et al. J Clin Psychiatry. 2016 Mar.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. OCD Severity Over Four Weeks (n=8)a
aAfter a single 40-minute infusion of ketamine 0.5mg/kg, 10 hours of exposure sessions were delivered over two weeks. Estimated means from mixed-effects regression are plotted with standard error. Patients had mean illness duration of 20.5 years (with standard deviation [SD] 10.2 years). The mean number of adequate SRI trials was 1.8 (SD 1.4), 80% received at least one prior adequate trail of an SRI, 10% failed at least one prior adequate trial of antipsychotic augmentation, and 60% had failed at least one prior adequate trial of EX/RP. Observed mean YBOCS score with standard deviation were as follows: Baseline: 28.8 (SD 4.6); Week 2: 18.3 (SD 8.9); Week 4: 21.9 (SD 9.8). Abbreviation: CBT = cognitive-behavioral therapy.
See this image and copyright information in PMC

References

    1. Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013 Nov;38(12):2475–2483. - PMC - PubMed
    1. Rodriguez CI, Kegeles LS, Flood P, Simpson HB. Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011 Apr;72(4):567–569. - PMC - PubMed
    1. Bloch MH, Wasylink S, Landeros-Weisenberger A, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012 Dec 1;72(11):964–970. - PMC - PubMed
    1. Duman RS. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress Anxiety. 2014 Apr;31(4):291–296. - PMC - PubMed
    1. Liu RJ, Lee FS, Li XY, Bambico F, Duman RS, Aghajanian GK. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry. 2012 Jun 1;71(11):996–1005. - PMC - PubMed

Publication types